Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?

Table 4 Adjusted ORs for different measure of PSA testing/results associated with uptake of AS in men with low/very low risk PCa (History for the 5-year period before diagnosis)

PSA and Biopsy measures	OR	95% CI	p-value
Total number of PSA tests (continuous)	0.99	0.96–1.02	0.672
Total number of PSA tests excluding repeat tests (test within 60 days of previous test)	0.99	0.96–1.03	0.597
Highest pre-diagnostic total-PSA level (per ng/mL)	0.98	0.95–1.02	0.332
Mean PSA velocity (earliest to diagnostic PSA level)	0.98	0.96–1.01	0.133
Any previous negative prostate biopsy	1.11	0.90–1.38	0.329
Total number of previous biopsies (continuous)	1.04	0.88–1.21	0.669

CI confidence interval, OR odds ratio, PSA prostate specific antigen
ORs derived from separate multivariable logistic regression models adjusted for age, education level, civil status, CCI, family history, symptoms, diagnosis year and risk category (and number of previous PSA tests/biopsies)

ISSN: 1471-2490